Physician profile
Luis Glodowski
NPI 1477508158
$14,284.29
in general payments reported to CMS, 2019-2025
38 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,086 · 2020: $2,527 · 2021: $2,891 · 2022: $2,225 · 2023: $2,408 · 2024: $1,675 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,516 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,516.21 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,311.34 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $1,744.91 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,291.92 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,128.23 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,018.37 | 2019-2024 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $803.93 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $741.00 | 2019-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $604.49 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $498.82 | 2019-2024 | Verquvo |
| Novo Nordisk INC | $440.93 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $366.71 | 2019-2024 | |
| Pfizer INC. | $291.02 | 2019-2024 | |
| Medtronic Vascular, INC. | $262.31 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.33 | 2020-2024 | Xifaxan |
| Amgen INC. | $225.37 | 2019-2025 | Repatha |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Glodowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.